Ibuprofen Trelamine

Summary

Ibuprofen Trelamine (CHEMBL5314598) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including osteoarthritis and pain agnosia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 6
• Chemistry: 305.5 Da · C19H31NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314598
Name	Ibuprofen Trelamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	127633
Molecular formula	C19H31NO2
Molecular weight	305.5
InChIKey	LMNZWAJFILAFEC-UHFFFAOYSA-N

SMILES: CCN(CC)CCOC(=O)C(C)C1=CC=C(C=C1)CC(C)C

IUPAC name: 2-(diethylamino)ethyl 2-[4-(2-methylpropyl)phenyl]propanoate

Also known as: Diethylaminoethyl ibuprofen, Ibuprofen diethylaminoethyl ester, Ibuprofen trelamine, X-0002 FREE BASE, X0002, X0002 FREE BASE, IBUPROFEN TRELAMINE

Parent form; salt/anhydrous children: CHEMBL5314599

Patent coverage: 9 distinct patent families (37 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis	3	MONDO:0005178	MONDO:0005178
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616
pain agnosia	1	MONDO:0000675	EFO:1001484

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03081806	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain
NCT03110523	PHASE3	WITHDRAWN	A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine
NCT05324163	PHASE3	COMPLETED	Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
NCT02067611	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis
NCT03691818	PHASE2	COMPLETED	Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
NCT02794740	PHASE1	COMPLETED	Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).